Detection of the Multiple Sclerosis Drug Siponimod Using Fluorine-19 Magnetic Resonance Imaging
Ludger Starke1,2, Mariya Aravina1, Jason M. Millward1, Thoralf Niendorf1,3, and Sonia Waiczies1
1Berlin Ultrahigh Field Facility, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, 2Digital Health Center, Hasso Plattner Institute, Potsdam, Germany, 3Experimental and Clinical Research Center (ECRC), A Joint Cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany
Siponimod is a fluorinated drug approved for treatment of secondary progressive multiple sclerosis. We detect 19F-MR signal in the liver, brain, kidneys, and thymus, and achieve the first 19F-MR images of a disease modifying drug, both in the liver and brain ex vivo and in a proof-of-concept in vivo experiment. Clear concentration differences between lobes of the liver or regions of the CNS can be observed. We have demonstrated the feasibility of using 19F-MRI to study the distribution of disease modifying drugs and improve our understanding of pharmacokinetics or guide therapeutic decisions.
This abstract and the presentation materials are available to members only;
a login is required.